TICKERNERD
Menu
AGIOAGIOHealthcare · Biotechnology

AGIO Stock Forecast: Agios Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$31
−17.96% on the day

The 10 Wall Street analysts covering Agios Pharmaceuticals, Inc. hold a median 12-month price target of $44 — +42.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 74 of 100 as at 31 Oct 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$1.8B
Ticker Nerd rank
74/ 100
Median analyst target
$44
Analysts covering
10
Revenue$44.7M+259.3% y/y
Operating income−$110.6M
Net income−$100.7M
Free cash flow−$83.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−17.4%
1M
−8.1%
YTD
+12.2%
1Y
−29.3%
From 52W high
−32.9%
From 52W low
+36.7%
$22
$45
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AGIO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Agios Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
74/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
78
Accruals
72
Issuance
72
Revisions
66
Growth
64
Value
61
Momentum
46
Volatility
43
Size
36

Quality (78): The business earns solid, repeatable profits on what it owns.

Volatility (43): The share price moves around a lot.

Size (36): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

AGIO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AGIO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60$70Jan 26Apr 26Jul 26Oct 26AGIOHigh $72Median $44Low $32

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
7 Buy3 Hold0 Sell
Low $32Median $44High $72

The green dot is the last close — the median target sits +42.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
29 Oct 2026HC Wainwright & Co.AssumesBuy$55
7 Oct 2026Truist SecuritiesMaintainsBuy$39 → $37
21 Sept 2026B of A SecuritiesMaintainsBuy—
21 Sept 2026B of A SecuritiesMaintainsBuy$46 → $50
7 Aug 2026JP MorganMaintainsNeutral$31 → $34
7 Aug 2026JP MorganMaintainsNeutral—
31 July 2026CitigroupMaintainsBuy$46 → $52
31 July 2026CitigroupMaintainsBuy—
31 July 2026Truist SecuritiesMaintainsBuy$41 → $39
31 July 2026Truist SecuritiesMaintainsBuy—
30 July 2026HC Wainwright & Co.MaintainsBuy—
30 July 2026HC Wainwright & Co.MaintainsBuy$52 → $55
21 July 2026HC Wainwright & Co.MaintainsBuy$54 → $52
21 July 2026HC Wainwright & Co.MaintainsBuy—
7 July 2026B of A SecuritiesMaintainsBuy$40 → $46
7 July 2026B of A SecuritiesMaintainsBuy—
7 July 2026RBC CapitalMaintainsSector Perform$28 → $32
7 July 2026RBC CapitalMaintainsSector Perform—
7 July 2026Truist SecuritiesMaintainsBuy—
7 July 2026Truist SecuritiesMaintainsBuy$36 → $41

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

AGIO appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

AGIO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, Agios Pharmaceuticals, Inc. returned −29.3% against +12.4% for the S&P 500, dividends included.

AGIO vs S&P 500, last 12 monthsTotal return, rebased to 100
5060708090100110120Jan 26Apr 26Jul 26Oct 26AGIOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AGIO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
3
Fundamentals

Agios Pharmaceuticals, Inc. (AGIO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
3.8×

Cheaper than 67% of US stocks

Price / sales
18.5×

Cheaper than 9% of US stocks

Price / book
1.8×

Cheaper than 47% of US stocks

EV / EBITDA
−2.7×

Cheaper than 78% of US stocks

Growth & margins
Revenue growth (YoY)
259.3%

Higher than 96% of US stocks

Earnings growth (YoY)
259.3%

Higher than 92% of US stocks

Gross margin
93.3%

Higher than 97% of US stocks

Operating margin
−247.1%

Higher than 10% of US stocks

Net margin
88.3%

Higher than 99% of US stocks

Returns & dividend
Return on equity
−34.3%

Higher than 26% of US stocks

Return on assets
−22.2%

Higher than 18% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Agios Pharmaceuticals, Inc. (AGIO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Agios Pharmaceuticals, Inc. has a market value of $1.8B and an enterprise value of $1.2B.

  • Revenue in the twelve months to 30 June 2026: $98.3M. The latest quarter grew 259.3% year on year.

  • Net income over the same four quarters: −$411.3M, a −418.2% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$390.3M.

  • Shares outstanding: 59.6M.

  • Trailing P/E: 3.8×; forward P/E: −7.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Agios Pharmaceuticals, Inc. employs 539 people — $182K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 1 Nov 2026

Data provided by Twelve Data

Peers

AGIO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
AGIOAgios Pharmaceuticals, Inc.$1.8B74
ADRXADARx Pharmaceuticals, Inc.$1.8B0
GENBGenerate Biomedicines, Inc.$1.8B1
ZBIOZenas BioPharma, Inc.$1.8B23
ABSIAbsci Corp.$1.9B37
TRAXFirst Tracks Biotherapeutics, Inc.$1.9B1
VIRVir Biotechnology, Inc.$1.9B93

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Agios Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AGIO news & analysis

Agios: News On Sickle Cell Approval Decision Delay May Not Derail Bull Thesis (Upgrade)

Seeking Alpha · 30 Oct 2026negative

Agios shares fell more than 15% after the FDA extended its review of mitapivat for sickle cell disease, setting a new PDUFA date in February 2027. The excerpt says the delay concerns safety and REMS considerations, while efficacy data were mixed and updated safety data reported no new hepatocellular injury cases.

Why it matters — AGIO watchers may weigh the longer regulatory timeline alongside mixed efficacy results and the FDA's safety-focused review.

Agios Announces New PDUFA Goal Date of February 1, 2027, for Mitapivat Sickle Cell Disease sNDA; Company Is Launch-Ready and in Labeling Discussions with FDA

GlobeNewsWire · 30 Oct 2026neutral

Agios said the FDA extended the PDUFA goal date for mitapivat’s sickle cell disease sNDA to February 1, 2027, after classifying the company’s response to a request for information about a potential REMS as a major amendment. The company said labeling discussions with the FDA will continue during the review.

Why it matters — The extension pushes the FDA’s review timeline back three months, while the potential REMS and labeling remain under discussion.

AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know

Zacks Investment Research · 6 Oct 2026negative

Agios faces a narrower growth path after setbacks for tebapivat, shifting attention to mitapivat sales, SCD expansion and regulatory prospects. The headline reports AGIO stock sank 29% in three months.

Why it matters — The setbacks and resulting focus on other products and prospects shape the company’s growth outlook for AGIO watchers.

FAQ

Frequently asked questions about AGIO stock

What is the AGIO stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Agios Pharmaceuticals, Inc. have a median 12-month price target of $44, with estimates ranging from $32 to $72. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AGIO stock a buy right now?

Of the 10 analysts covering Agios Pharmaceuticals, Inc., 7 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Agios Pharmaceuticals, Inc. 74 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AGIO?

As at 31 Oct 2026, Agios Pharmaceuticals, Inc. ranks 74 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (78 of 100).

Will AGIO stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +42.4% from the last close, and Ticker Nerd's factor model ranks Agios Pharmaceuticals, Inc. 74 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AGIO stock forecast for 2030?

No analyst covering Agios Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AGIO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $32 to $72 over the next 12 months.

How has AGIO stock performed over the past year?

Agios Pharmaceuticals, Inc. returned -29.3% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Agios Pharmaceuticals, Inc. do?

Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing medicines for rare diseases through its expertise in cellular metabolism.

What is the latest news on AGIO?

The most recent item we track (Seeking Alpha, 30 Oct 2026): "Agios: News On Sickle Cell Approval Decision Delay May Not Derail Bull Thesis (Upgrade)". Agios shares fell more than 15% after the FDA extended its review of mitapivat for sickle cell disease, setting a new PDUFA date in February 2027. The excerpt says the delay concerns safety and REMS considerations, while efficacy data were mixed and updated safety data reported no new hepatocellular injury cases.

Company

About Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing medicines for rare diseases through its expertise in cellular metabolism. The company’s core commercial product is PYRUKYND (mitapivat), an oral pyruvate kinase activator used in hemolytic anemia associated with pyruvate kinase deficiency, with additional development in other hematologic and genetically defined disorders. Agios is also advancing investigational therapies for conditions such as thalassemia, sickle cell disease, and phenylketonuria, reflecting its emphasis on rare disease biology and precision medicine. The company operates as a specialized hematology and rare disease developer, combining drug discovery, clinical development, and commercialization capabilities to address unmet medical needs. Agios Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

CEO Mr. Brian M. Goff M.B.A. · 539 employees · United States · https://www.agios.com